Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy

Authors

Aditi Dhir, University of Alabama at Birmingham
David R. Kelly, Children's of Alabama
Raymond G. Watts, LSU Health Sciences Center - New OrleansFollow
Matthew A. Kutny, University of Alabama at Birmingham

Document Type

Article

Publication Date

4-3-2020

Publication Title

Journal of pediatric hematology/oncology

Abstract

Langerhans cell histiocytosis (LCH) often has a recurrent and refractory course despite multiagent treatment modalities. Common relapse treatments include intense or prolonged cytotoxic chemotherapy regimens. There are a few prior reports that the nonsteroidal anti-inflammatory drug indomethacin demonstrated activity against bone LCH. Here we report indomethacin as a successful treatment for a case of chronic skin LCH that failed multiple prior chemotherapy regimens. This experience supports the need for trials to investigate indomethacin as a treatment for LCH both in the relapsed or refractory setting as well as potential combination or maintenance therapy in newly diagnosed patients.

PubMed ID

30951019

Volume

42(8)

Recommended Citation

Dhir, Aditi; Kelly, David R.; Watts, Raymond G.; and Kutny, Matthew A., "Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy" (2020). School of Medicine Faculty Publications. 1747.
https://digitalscholar.lsuhsc.edu/som_facpubs/1747
10.1097/MPH.0000000000001474